Genentech’s Refillable Implant Extends Treatment Time for Wet AMD Patients in Phase II Study

July 27, 2018: By Joan McKenna

Genentech’s port delivery system with ranibizumab implant in eye with refill needle 

Genentech announced positive top line results July 25 from a Phase II study evaluating its port delivery system (PDS) with ranibizumab, a refillable eye implant, in patients with wet age-related macular degeneration (AMD).

The majority of treated patients in the LADDER study went six months or longer between the implant of the device and the first required refill, and patients in the high-dose group achieved similar visual outcomes as monthly ranibizumab eye injections, Genentech said.

The implant, which is slightly longer than a grain of rice, is intended to allow people with wet AMD to go several months before needing a refill. It also is designed to address undertreatment that could lead to vision loss.

The PDS is implanted during a surgical procedure. It is refilled using a customized needle in a minimally invasive office-based procedure.

Carl Awh, MD, of Tennessee Retina, presented the results at the 2018 meeting of the American Society of Retina Specialists.

San Francisco-based Genentech, a member of the Roche Group, said it expects its Phase III program to begin later in 2018.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Astellas Acquires Quethera, Glaucoma Gene Therapy Candidate in Potential $109 Million Deal

STAAR Surgical Completes $77.9 Million Public Offering

Rheon’s eyeWatch Adjustable Glaucoma Device Implanted in Three UK Patients

Carl Zeiss Meditec Revenues Total $356 Million in Third Quarter of FY2018, a 12.7 Percent Increase

Kedalion Therapeutics Raises $5 Million in Series A Financing

Second Sight Reports 17 Argus II Implantations in Q2-2018; Firm to Focus on Orion System

Iridex Revenues Grow 3 Percent in Q2-2018

Omeros Revenues Drop Steeply with Omidria’s Temporary Loss of Pass-through Status

Shire’s Xiidra Delivers $100 Million in Q2-2018 Revenues, an Increase of 75 Percent

STAAR Posts Q2-2018 Revenues of $33.9 Million, a 55 Percent Increase

Avedro Names Glaukos CEO Thomas Burns to its Board

Aerie Licenses DSM’s Bioerodible Implant Technology for Ophthalmic Use for $15 Million

Alimera’s Q2-2018 Revenues Increase 5 Percent

Presbyopia Therapies’ PRX Meets Phase IIb Endpoints

Clinical Study of Imprimis’ Dropless Formulation Set to Begin in Canada

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT